Drug
Nbi 1117567
Nbi 1117567: highest development phase Phase 2, developed by Neurocrine Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-1117567 NCT07832383 | Phase 2 | Alzheimer's Disease |
Latest
No recent events.
Follow Nbi 1117567 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.